



Molecular Mechanisms of Steroid Hormone Action

Guest Editor:

Dr. Omar Cauli

Department of Nursing,
University of Valencia, 46010
Valencia, Spain

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editor

Dear colleague,

Hormone therapy is frequently used in the treatment of certain types of cancer and other disorders, by means of a set of measures, mainly the use of drugs aimed at inhibiting the function of certain hormones. In the case of cancers, its efficacy is based on the fact that certain tumors are hormone-dependent, since sex hormones favor their growth, both estrogens in the case of women and androgens in men. The importance of hormone therapy in the treatment of cancer is due to the fact that it improves survival and produces fewer side effects than chemotherapy. The use of hormonotherapy in menopause-associated disorders or endocrine disorders such as those affecting the thyroid and adrenal glands is of particular interest. Consolidated pharmacological approaches as well as new clinical indications are emerging for hormonotherapy. This Special Issue is devoted to providing an update on the research into hormonotherapy, from a molecular perspective to preclinical studies.

Prof. Dr. Omar Cauli
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI